company background image
RGLS

Regulus Therapeutics NasdaqCM:RGLS Stock Report

Last Price

US$1.72

Market Cap

US$29.0m

7D

2.4%

1Y

-49.4%

Updated

03 Dec, 2022

Data

Company Financials +
RGLS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

RGLS Stock Overview

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.

Regulus Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regulus Therapeutics
Historical stock prices
Current Share PriceUS$1.72
52 Week HighUS$4.00
52 Week LowUS$1.33
Beta1.62
1 Month Change18.62%
3 Month Change21.13%
1 Year Change-49.41%
3 Year Change-77.95%
5 Year Change-98.42%
Change since IPO-99.66%

Recent News & Updates

Regulus surges 15% after Phase 1 data for kidney disease candidate

Sep 12

Recent updates

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Oct 12
Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13
Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10
Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Shareholder Returns

RGLSUS BiotechsUS Market
7D2.4%4.2%1.5%
1Y-49.4%-7.4%-14.9%

Return vs Industry: RGLS underperformed the US Biotechs industry which returned -10.3% over the past year.

Return vs Market: RGLS underperformed the US Market which returned -16.1% over the past year.

Price Volatility

Is RGLS's price volatile compared to industry and market?
RGLS volatility
RGLS Average Weekly Movement10.8%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: RGLS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: RGLS's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200727Jay Haganhttps://www.regulusrx.com

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.

Regulus Therapeutics Inc. Fundamentals Summary

How do Regulus Therapeutics's earnings and revenue compare to its market cap?
RGLS fundamental statistics
Market CapUS$28.97m
Earnings (TTM)-US$28.66m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGLS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$18.11m
Gross Profit-US$18.11m
Other ExpensesUS$10.56m
Earnings-US$28.66m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.70
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio11.3%

How did RGLS perform over the long term?

See historical performance and comparison